Canada’s Aurora Cannabis has moved into the US market through the acquisition of peer Reliva in a deal that could be worth up to US$85m.

Both Aurora and Reliva market a wide-range of hemp-derived CBD products including edibles. Edmonton-based Aurora produces CBD-laced dark chocolate, cookies and gummies while Reliva, based in Natick, Massachusetts, also produces gummies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Aurora said entry into the US is aligned to its business transformation plan.

Its interim CEO Michael Singer said: “Together, Aurora and Reliva will partner to create an international cannabinoid leader that we believe can deliver robust revenue and profitable growth.”

“We have taken the time necessary to carefully assess the company’s entry into the US market and we firmly believe that the combination with Reliva will create significant long-term value as Reliva provides us options to grow in hemp-derived CBD internationally.”

Reliva CEO Miguel Martin said: “We were fortunate enough to be able to choose our long-term partner and believe this partnership provides a significant opportunity to accelerate sales growth for Reliva in the United States and internationally.”

Under the terms of the deal, members of Reliva will receive approximately US$40m of Aurora common shares. The transaction also includes a potential earn-out of up to a maximum of $45m payable in Aurora shares, cash or a combination over the next two years contingent upon Reliva achieving certain financial targets.